US post-election buzz: a tale of stem cells, trade agreements and power struggles
This article was originally published in Scrip
One week after US voters elected Illinois Democratic senator Barack Obama as their next president, we offer a few interesting post-election titbits on which Scrip's Washington bureau is keeping an eye (and this does not involve use of a crystal ball or a Ouija board to divine the name of the next FDA commissioner).
You may also be interested in...
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.
Communication and education on samidorphan’s opioid antagonistic effects should focus on health care providers that prescribe opioids as well as psychiatrists that prescribe olanzapine, advisory committee says in endorsing the safety and efficacy of ALKS 3831.